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Abstract
Endothelial cells play a critical role in maintaining the integrity of vascular 
structure and function. Endothelial dysfunction is closely associated with the 
development and progression of cardiovascular diseases (CVDs) like hypertension 
(HTN) and atherosclerosis. Gut microorganisms significantly contribute to 
atherosclerosis and related CVDs. Helicobacter pylori (H. pylori) colonizes in 
human gastric epithelium in a significant portion of general population in the 
world. Patients with H. pylori infection have significantly increased risk for CVDs 
including atherosclerosis, HTN, coronary heart disease, and cerebrovascular 
disease especially in younger patients (< 65 years old). H. pylori infection 
significantly impairs vascular endothelial function through multiple mechanisms 
including increased reactive oxygen species production and oxidative stress, 
inflammation, decreased nitric oxide formation, modification of the expression of 
cytokines and microRNAs, abnormalities of lipid and glucose metabolisms, and 
exosomes-mediated pathways. Endothelial dysfunction associated with H. pylori 
infection is reversible in both animal model and human subjects. Accumulating 
data suggests that H. pylori infection is an important risk factor for endothelial 
dysfunction and CVDs especially in young patients. Screening young male 
population for H. pylori infection and treating accordingly could be an effective 
approach for early prevention of CVDs especially premature atherosclerosis 
associated with H. pylori infection.
Keywords: Helicobacter pylori, atherosclerosis, endothelial dysfunction, 
cardiovascular disease, exosomes
1. Introduction
Atherosclerosis is among the principal contributors to cardiovascular diseases 
(CVDs) especially coronary artery diseases (CAD) and stroke [1]. Despite in-depth 
understanding of the traditional cardiovascular risk factors including diabetes 
mellitus (DM), hypertension (HTN), hyperlipidemia, smoking, and obesity, 
and effective control of these known risk factors, CVDs remain the leading cause 
of mortality and morbidity in developed countries including the US [2, 3]. It is 
worrisome that the decline of all cardiovascular mortality rate has been slowing 
down since 2011 [4]. It is very problematic that patients presenting with ST 
elevation myocardial infarction over the past 20 years are getting younger [5], 
and the total number of death from CAD and stroke is projected to increase by 
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about 18% by 2030 [6]. Clearly, there are other risk factors that have not been 
defined, and yet contribute significantly to the development and progression of 
atherosclerosis and related CAD and stroke.
Gut microorganisms significantly contribute to the development of 
atherosclerosis and related CVDs [7–9]. The microaerophilic Gram-negative 
bacterium Helicobacter pylori (H. pylori) colonizes in the epithelium of human 
stomach in a significant portion of general population in the world with the 
infection rate ranging from 30% - 50% in developed countries up to 80% in 
developing countries especially in Asia [10, 11]. Most patients with H. pylori 
infection have no symptoms clinically [12]. However, H. pylori infection could cause 
progressive damage to gastric mucosa, and is closely associated with a number of 
important diseases including (but not limited to) chronic gastritis, peptic ulcers, 
and gastric cancer [13]. Recent data indicate that H. pylori infection could also 
contribute to some important extra gastrointestinal diseases such as hematological 
diseases (especially idiopathic thrombocytopenia), neurological abnormalities, 
dermatological pathologies, and autoimmune disorders like inflammatory bowel 
diseases, chronic liver disease, and DM [14–22]. Thus, H. pylori infection is a 
significant cause of morbidity and mortality in humans. In 2005, Dr. Barry Marshall 
and Dr. Robin Warren were awarded the Nobel Prize in Physiology for their 
pioneering work on H. pylori.
Growing evidences indicate that H. pylori infection could also contribute 
to CVDs. A recent meta-analysis with a large population showed that H. pylori 
infection increased the risk of adverse cardiovascular events by 51%, mostly due 
to myocardial infarction and cerebrovascular disease [23]. Data also suggests that 
H. pylori infection increases the risk of coronary heart diseases (CHD) and related 
events predominantly in a patient’s early life [24], and is positively associated with 
HTN [25, 26]. In this chapter, efforts will be focused on: 1) brief overview on the 
association of H. pylori infection and CVDs; 2) relationship between H. pylori 
infection and atherosclerosis; 3) H. pylori infection and endothelial dysfunction; 
4) role of exosomes in mediating the effect of H. pylori infection on endothelial 
function, and 5) significance and clinical implications.
2. Brief overview on H. pylori infection and cardiovascular diseases
The role of H. pylori infection in the development and progression of CVDs 
has been established for the past two decades. Early epidemiology studies have 
suggested an association between H. pylori infection and increased prevalence 
of atherosclerosis [27] An early study that included 96 patients with CAD and 96 
patients without CAD has revealed the followings: 1) there is a significant link 
between CAD and infection with H. pylori, especially the one expressing the viru-
lence factor cytotoxin-associated gene A (CagA) proteins, 2) patients infected with 
CagA-positive H. pylori show significantly greater coronary artery lumen loss and 
arterial re-stenosis after percutaneous transluminal coronary angioplasty (PTCA) 
with stent implantation, 3) H. pylori eradication significantly attenuates the reduc-
tion in coronary artery lumen in CAD patients after PTCA [28]. Diabetic subjects 
with H. pylori infection have more severe peripheral arterial stiffness compared 
with those without H. pylori infection, and a higher cardiovascular risk score and 
10-year cardiovascular risk stratification [29, 30]. After adjusting for traditional 
CVD risk factors, H. pylori infection is found to be the only independent predic-
tor of incident carotid plaque with the multivariate odds ratio (OR) of 2.3, and 
incident acute stroke (with multivariate OR of 3.6) [31]. H. pylori infection was 
positively associated with the prevalence of HTN among Chinese adults [25, 26].  
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Recently, a study using cardio-ankle vascular index reported that subjects with 
positive H. pylori serology were significantly associated with increased arterial 
stiffness [32].
A recent study, using a large database with a total of 208,196 patients diagnosed 
with peptic ulcer diseases, compared the cardiovascular outcome for subjects 
with and without H. pylori eradication. A total of 3,713 patients with H. pylori 
eradication treatment within 365 days of the index date were included in the study 
with randomly selected same number of patients using propensity scores as cohort 
of non-eradication patients for comparison. The study demonstrated that there 
was a significant decrease in composite end-points for CHD and death in the early 
eradication group. The cumulative CHD rate was significantly lower in younger 
patients (< 65 years old) with H. pylori eradication therapy started <1 year of the 
index date compared to those patients without eradication at all. Interestingly, the 
study also showed that eradication treatment did not appear to have a significant 
effect in older patients (≥ 65 years old). Multivariate analysis shows that HTN 
and renal diseases are risk factors for CHD in patients without eradication, while 
younger age (< 65 years old) was a protective factor for CHD for the patients 
with H. pylori therapy [33]. Thus, there is little doubt that H. pylori infection is 
indeed associated with significant CVDs including atherosclerosis, HTN, CHD, 
cerebrovascular disease, and peripheral arterial diseases, as well as their clinical 
outcomes especially in younger patients (< 65 years old).
3. Helicobacter pylori infection and carotid atherosclerosis
The relationship between H. pylori infection and atherosclerosis has been 
inconsistent and sometimes controversial with the findings from a strong positive 
association, and a mild association, to no association [27, 34–36]. Compared to 
those without H. pylori infection, patients with H. pylori infection, especially with 
CagA+ H. pylori, have much higher incidence of atherosclerosis (29% vs. 63%) [37], 
and acute ischemic stroke (45% vs. 77%) [17]. The prevalence of serologically con-
firmed H. pylori infection was significantly higher in patients with angiographically 
documented CAD, supporting a positive association between H. pylori infection 
and CAD [38–40]. However, a meta-analysis with inclusion of 18 epidemiological 
studies and over 10,000 patients showed no positive relationship between H. pylori 
infection and CAD [41]. In contrast, the data supporting a positive relationship 
between H. pylori infection and carotid atherosclerosis with increased carotid 
intima-media thickness (CIMT) were consistent in most of the studies with 
patients [17, 42–45]. The reason(s) for the significant difference in consistency on 
the relationship between H. pylori infection and CAD vs. carotid atherosclerosis is 
unclear. It could be very likely due to the different imaging modalities used for the 
detections of CAD (using coronary angiogram) and carotid atherosclerosis (using 
carotid ultrasound). Carotid ultrasound could easily detect early atherosclerotic 
lesions without significant loss of vascular lumen, while coronary angiogram 
could not. In a recent study, the investigators used cardiac multidetector computed 
tomography to identify subclinical coronary atherosclerotic lesions in healthy 
subjects without clinical CVD, and found that patients with current H. pylori 
infection was 3-fold more likely to have subclinical and yet significant coronary 
atherosclerosis than the patients without H. pylori infection [15]. One of the major 
features of atherosclerosis is thickening of the intima-media in the arteries that 
could not be detected with angiogram. Carotid artery is considered an early site of 
atherosclerosis, and superficially located. Thus, carotid ultrasound examination 
is an ideal and sensitive non-invasive image modality to diagnose and monitor the 
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progression of atherosclerosis [46], although it has not been widely used clinically 
for atherosclerosis screening at this point.
Recently, a large patient database of 17,613 adult patients with carotid ultrasound 
examination and a 13C-urea breath H. pylori test was analyzed [47]. Based on the 
study designs, the patients were divided into two groups: a cross-sectional study for 
single measurement group, and a retrospective cohort study for the patients with 
follow up measurements up to 5 years. Patients were excluded from the study if any 
of the following conditions was present: 1) history of H. pylori eradication, 2) use 
of any antibiotics, proton pump inhibitors, or H2-receptor blockers 3 months before 
the tests, 3) age < 20 or > 70 years, 4) connective tissue diseases or immunological 
diseases, 5) mental disorders, 6) asthma or COPD, 7) hematological disorders, 8) 
thyroid diseases, 9) malignancies, 10) recent (within 3 months) or chronic infec-
tion (over 3 months) except H. pylori infection, 11) congestive heart failure, and 12) 
abnormal liver or kidney function. Patients with CAD were not excluded from the 
study since carotid atherosclerosis and CAD share similar risk factors, and it was 
felt that exclusion of the subjects with CAD could remove the subgroup population 
who might be at increased risk for carotid atherosclerosis with H. pylori infection, 
leading to potential selection bias. Of note, the patients with CAD accounted only 
for about 3% of all participating subjects for this study, and there was no stroke in 
the patients in the database.
The data showed that, after adjusting for age, sex, body mass index, lipid 
profile, HTN, DM, and smoking, H. pylori infection was an independent risk 
factor for carotid atherosclerosis in male patients ≤50 years, but not in older 
males or females (OR of 1.229, p = 0.009). The data also demonstrated that H. 
pylori infection was associated with a significant increase in CIMT for males, 
not females. To further evaluate the relationship between H. pylori infection and 
carotid atherosclerosis, the investigators studied the 5 years follow up data on 
additional 2,042 subjects with and without H. pylori infection for progression 
on the prevalence of carotid atherosclerosis with annual carotid ultrasound 
examination and a 13C-urea breath test. The data showed that for males with age of 
<50 years, there was a 22.5% increase in the prevalence of carotid atherosclerosis 
in the subjects with H. pylori infection compared with the ones without H. pylori 
infection. These data demonstrated that H. pylori infection selectively increased the 
risk for carotid atherosclerosis in young males under 50 years old [47]. However, 
how H. pylori infection could lead to atherosclerosis, and why only in young males 
is unknown.
4. H. pylori infection and endothelial dysfunction
4.1 H. pylori infection and endothelial dysfunction in patients
Endothelial cells play a critical role in maintaining the integrity of vascular 
structure and function. Endothelial dysfunction is an important contributing factor 
to the pathogenesis of CVDs including HTN and atherosclerosis [4]. Early studies 
with small patient samples suggested that there was no clear association between 
chronic infections, including infection with Chlamydia pneumoniae, cytomegalo-
virus, Epstein–Barr virus, and H. pylori, and decreased endothelial function [48]. 
A small study with a total of 53 pediatric patients using Doppler ultrasonography 
of the brachial artery showed that percent ratio of the change in systolic diameters 
during hyperemic phase to the basal diameter (endothelium-dependent) was not 
significantly different between H. pylori-negative and -positive groups in pediatric 
population [49].
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However, accumulating data clearly supports the concept that H. pylori infection 
could lead to significant endothelial dysfunction in patients. Using high-frequency 
ultrasonographic imaging of the brachial artery, it was found that endothelium-
dependent flow-mediated vasodilation (FMD) was significantly lower in the subjects 
with seropositive antibodies to H. pylori than in the ones with seronegative antibodies 
to H. pylori, while endothelium-independent nitroglycerin-induced vasodilation was 
similar in both groups [50]. Similarly, another study with patients with chronic gastritis 
associated with H. pylori infection demonstrated that the level of FMD in patients 
with positive H. pylori infection was significantly lower than those with negative H. 
pylori infection and the healthy control group [51]. Studies also showed that the levels 
of C-reactive protein and soluble intercellular adhesion molecule-1 (ICAM-1) were 
significantly higher in subjects with seropositive antibodies to H. pylori than in those 
with seronegative antibodies to H. pylori [50]. The levels of endothelial dysfunction 
biomarkers, including endothelin-1 (ET-1), E-selectin, and ICAM-1, were found to be 
significantly higher in H. pylori (+) patients than in H. pylori (−) subjects [52].
One of the important questions is whether endothelial dysfunction associ-
ated with H. pylori infection is reversible. In a study in 2011, vascular function 
measurements (ankle brachial index and flow-mediated diameter percent change) 
were made in patients with H. pylori infection at the time of study enrollment and 
3 months afterwards with H. pylori eradication. Subjects with H. pylori infection 
were treated with standard triple antibiotics therapy. It was found that H. pylori-
positive subjects had severe endothelial dysfunction that improved significantly 
after H. pylori eradication with triple antibiotics. Subjects without H. pylori 
infection also had endothelial dysfunction, however, that was not improved after 
treatment with triple antibiotics. These data suggests that endothelial dysfunction 
in patients with H. pylori infection appear to be reversible [53].
In a recent study, the investigators carefully selected 18 young patients (both male 
and female) with H. pylori infection without any known risk factors for endothelial 
dysfunction to evaluate endothelium-dependent FMD of the brachial artery with 
ultrasound. A group of 13 age- and sex-matched young healthy volunteers served as 
the controls. The diagnosis of H. pylori infection was confirmed with gastric endo-
scopic biopsy and 13C urea breath test for each patient. No other confounding vari-
ables except the conditions listed in the exclusion criteria were considered for subject 
selection. Young patients were recruited to minimize the risk factors for endothelial 
dysfunction. Patients were excluded from the study if any of the following conditions 
was present: 1) history of H. pylori eradication, 2) use of any medications including 
antibiotics, proton pump inhibitors, or H2-receptor blockers 3 months before the 
study, 3) age < 18 or > 35 years, 4) connective tissue diseases or immunological dis-
eases, 5) mental disorders, 6) asthma or COPD, 7) hematological disorders, 8) thyroid 
diseases, 9) malignancies, 10) recent (within 3 months) or chronic infection except 
H. pylori infection, 11) congestive heart failure, 12) abnormal renal or liver function; 
13) congenital heart diseases, 14) hypertension, 15) smoking, 16) diabetes mellitus, 
17) lipid abnormalities, 18) stroke, 19) obesity, 20) sedentary life style, 21) alcohol 
use, 22) any use of energy drinks or coffee or tea within 48 hours, and 23) unrespon-
sive to anti-H. pylori therapy. After fasting for 8 to 12 hours, brachial artery FMD 
was evaluated for patients and control subjects, and presented as percent change in 
post-ischemia diameter over baseline. The data showed that patients with H. pylori 
infection exhibited a significant reduction in endothelium-dependent vasodilatation 
compared with the controls (Figure 1A). When patients with H. pylori infection were 
treated with BIS-based quadruple oral anti-H. pylori therapy (100 mg furazolidone, 
100 mg doxycycline, 5 mg ilaprazole, and 220 mg colloidal bismuth tartrate, twice 
a day for 2 weeks) [54], their endothelium-dependent FMD of the brachial artery 
was effectively restored (Figure 1B) [55]. The effectiveness of H. pylori eradication 
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with antimicrobial therapies was confirmed using 13C urea breath test for the study 
patients. These data confirms that endothelial dysfunction in patients with H. pylori is 
indeed reversible (very likely within 1 year of infection).
4.2 H. pylori infection and endothelial dysfunction in animal models
In the same recent study, the investigators used specific-pathogen-free male 
C57BL/6 mice to establish a mouse H. pylori infection model to determine if 
impaired endothelial function in human subjects with H. pylori infection could 
be re-produced in animal model using the H. pylori bacteria isolated from 
patients. Since the vast majority (>90%) of H. pylori infection patients in East or 
Southeast Asian countries are infected with CagA+ H. pylori [56, 57], and CagA 
is considered to be involved in the extragastric diseases associated with H. pylori 
infection [44, 58–60], CagA+ H. pylori bacteria isolated from gastric ulcer 
patients were prepared, characterized, and used for the animal experiments with 
phosphate buffer solution (PBS) as control. After fasting overnight, mice were 
infected with H. pylori inoculum in PBS by intragastric gavage once per day for 
3 days to achieve 100% infection rate. Successful infection with CagA+ H. pylori 
in mice was confirmed with both positive Rapid Urease Test (RUT) and Giemsa 
staining as described [61]. A 100% infection rate was achieved in C57BL/6 mice 
with this method. Control mice received the same volume of PBS by intragas-
tric gavage.
Thoracic aorta was collected to evaluate endothelium-dependent relaxation 
to acetylcholine (Ach) and endothelium-independent relaxation to nitroglycerin 
(NTG) at week 1, 8, 12, and 24 after H. pylori infection to determine if there was a 
significant difference in endothelial dysfunction after acute (1 week) and chronic 
(24 weeks) H. pylori infection. Indeed, Ach-induced endothelium-dependent 
relaxation was significantly reduced in mice 1 week after H. pylori infection without 
Figure 1. 
H. pylori infection significantly impairs endothelium-dependent flow-mediated dilatation (FMD) in human 
subjects and endothelium-dependent vascular relaxation in mice. Patients with H. pylori infection and healthy 
control subjects were evaluated for endothelium-dependent flow-mediated dilatation (FMD) of the brachial 
artery with ultrasound. The diagnosis of H. pylori infection was confirmed with gastric endoscopic biopsy and 
13C urea breath test for each patient. Patients with H. pylori infection (n = 18 patients) displayed a significant 
reduction in their endothelium-dependent FMD compared with the controls (n = 13 subjects) (A). Eradication 
of H. pylori infection with anti-H. pylori therapy effectively restored the endothelium-dependent FMD in 
patients with H. pylori infection (n = 10 patients with anti-H. pylori therapy) (B). Mice infected with CagA+ 
H. pylori for 1 week significantly decreased acetylcholine (Ach)-induced endothelium-dependent relaxation 
of thoracic aorta without change in nitroglycerin (NTG)-induced endothelium-independent vasorelaxation 
(data not shown) after sub-maximal contraction with phenylephrine (PE) (10−6 M). The impaired ach-
induced endothelium-dependent vasorelaxation persisted for as long as the infection was present for at least 
24 weeks (C) without change in NTG-induced endothelium-independent vasorelaxation (data not shown). 
Eradication of H. pylori infection with anti-H. pylori therapy effectively restored ach-induced endothelium-
dependent vasorelaxation in mice with 12 weeks of chronic CagA+ H. pylori infection, #p < 0.05 (compared to 
CagA+ H. pylori + treatment mice); **p < 0.01 (compared to NC mice) (C), n = 8 mice for each group. NC: 
Normal control; Ach: Acetylcholine; NTG: Nitroglycerin. Data were presented as mean ± SE. [adopted and 
modified from (55) with permission].
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change in NTG-induced endothelium-independent relaxation. The impaired Ach-
induced endothelium-dependent relaxation persisted for as long as the infection 
was present for at least 24 weeks in the infected mice without change in vascular 
contraction to either phenylephrine or potassium chloride (Figure 1C), while NTG-
induced endothelium-independent relaxation remained intact [55]. These data 
demonstrated that H. pylori infection selectively impairs endothelium-dependent 
relaxation, not endothelium-independent relaxation, of thoracic aorta in mice that 
are similar to the findings in human subjects with H. pylori infection.
Efforts were made to examine if eradication of H. pylori infection could improve 
endothelium-dependent vasodilation to confirm if H. pylori infection was indeed 
the reason for endothelial dysfunction. As expected, elimination of H. pylori 
infection in mice with anti-H. pylori therapy (123.3 mg/Kg bismuth potassium 
citrate, 102.75 mg/kg tinidazole, and 51.38 mg/kg clarithromycin once daily for 
2 weeks via intragastric gavage) significantly improved Ach-induced endothelium-
dependent vasorelaxation without change in NTG-induced endothelium-
independent relaxation (Figure 1C). For the control group, H. pylori infected 
mice were given the same volume of normal saline. The effectiveness of H. pylori 
eradication with antimicrobial therapies in mice was confirmed using RUT and 
Giemsa staining [55, 61]. These findings confirm that impairment of endothelium-
dependent vasodilation associated with H. pylori infection is reversible in mouse 
model, similar to the observations in human subjects.
4.3  Potential mechanisms for the effect of H. pylori infection on endothelial 
function
It is important to know how H. pylori infection leads to endothelial dysfunction. 
In vitro study using bovine aortic endothelial cells (BAECs) showed that treatment of 
BAECs with H. pylori-conditioned medium from H. pylori 60190 (vacuolating cyto-
toxin A) significantly decreased the proliferation, tube formation, and migration 
of the cells (by up to 44%, 65%, and 28%, respectively) through VacA-dependent 
reduction in the production of endothelial nitric oxide (NO) [62]. Culture of human 
umbilical vein endothelial cells (HUVECs) with H. pylori significantly inhibited the 
proliferation, migration, and tube formation of HUVECs, and increased the produc-
tion of the inflammatory factor Chitinase 3 Like 1 (CHI3L1) and phosphorylated 
p38 in endothelial cells associated with an increased expression of GATA3. Increased 
levels of GATA3 and CHI3L1 were also found in the arteries of mice with H. pylori 
infection. Knockdown of GATA3 could prevent H. pylori-induced dysfunction of 
HUVECs. These findings suggest that H. pylori might impair endothelial function 
through increased expression of GATA3 and production of CHI3L1 [63].
H. pylori urease (HPU) is considered a key virulence factor that enables bacteria 
to colonize and survive in the stomach. It has been shown that HPU could trigger 
the production of reactive oxygen species (ROS) in endothelial cells. Increased 
intracellular ROS could lead to activation of nuclear factor kappa B (NF-κB) and 
upregulate expressions of cyclooxygenase-2, hemeoxygenase-1, interleukin (IL)-1β, 
and ICAM-1, thus increasing oxidative stress and endothelial dysfunction [64]. 
H. pylori infection of primary human endothelial cells is reported to stimulate 
secretion of important inflammatory cytokines, IL-6 and IL-8 (especially IL-8) 
in endothelial cells [65]. Treatment of HUVECs with different CagA positive and 
negative H. pylori derived products could enhance the expressions of microRNAs 
(miRNAs) including miR-21, miR-155, and miR-663 in the cells that are associated 
with inflammation, apoptosis and necrosis of the cell [66]. Recently, it was reported 
that H. pylori infection could impair endothelial function through exosomes-
mediated mechanism [55]. This will be discussed in details below.
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5.  Role of exosomes in mediating the effect of H. pylori infection on 
endothelial function
H. pylori do not enter the blood circulation themselves because of the gastric 
tissue barrier and a unique survival and growth environment [67]. However, 
H. pylori virulence factor CagA and H. pylori DNA are present in human 
atherosclerotic lesions and human aorta, carotid and coronary arteries [44, 68–70]. 
Many cells are known to release extracellular vesicles with unique biophysical and 
biochemical properties [71, 72], that are referred as exosomes (with diameters 
from 30 to 200 nm) [73]. Exosomes are found in various body fluids including 
blood, urine, saliva, and breast milk, and play an important role in cell-to-cell 
communications through transport of a wide spectrum of bioactive constituents 
including proteins, lipids, and miRNAs [74, 75]. Recent studies have demonstrated 
that exosomes are critically involved in the transfer of proteins during infections 
like prion protein in neurodegenerative disease [76], human immunodeficiency 
virus-related proteins [77], and human T-cell leukemia virus type-1 proteins [78]. 
Indeed, it is shown that H. pylori infection increases the expression of miR-25 
in gastric epithelial cells and is associated with increased levels of exosome-
transmitted miR-25 in peripheral blood in human subjects. Further studies 
demonstrate that Kruppel-like factor 2 (KLF2) is a direct target of exosome-
transmitted miR-25 in vascular endothelial cells. MiR-25/KLF2 axis is involved in 
the regulation of NF-κB signaling pathway, resulting in increased expression of 
IL-6, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, and 
ICAM-1 [79].
To determine how H. pylori infection impairs endothelial function, a recent 
study tested the hypothesis that H. pylori could interact with gastric epithelial cells 
(GES-1), leading to the release of CagA-containing exosomes into the circulation 
that in turn impair endothelial function [55]. Indeed, Western blotting analysis and 
immunofluorescence staining demonstrated that the unique H. pylori virulence 
factor CagA entered into human GES-1 after incubation with CagA+ H. pylori 
(Figure 2A and B). Further studies showed that characteristic exosomes were 
present in the conditioned media of human GES-1cultured with CagA+ H. pylori 
as defined by specific biomarkers (HSP70 and CD9) using Western blotting, by 
specific morphologic features using transmission electron microscopy, and by size 
distribution using a Zetasizer Nano ZS instrument [80]. Western blotting analysis 
demonstrated that the exosomes from the conditioned media of human GES-1 
cultured with CagA+ H. pylori contained the unique CagA protein, while exosomes 
from the control conditioned media of GES-1 (without culture with H. pylori) 
had no CagA protein (Figure 2C-E). When the labeled GES-1-derived exosomes 
with PKH67 were cultured with HUVECs, a detectable amount of PKH67-labeled 
exosomes was present in HUVECs using 3-D confocal microscopy after 12 hours of 
culture (Figure 2F), confirming the entry of exosomes into HUVECs. Treatment 
with human GES-1-derived CagA-containing exosomes significantly inhibited the 
function of HUVECs with decreased proliferation, migration, and tube formation 
as compared with the control exosomes (Figure 2G-I).
Further studies [55], using the serum exosomes from patients with CagA+ H. 
pylori infection and from healthy age-and sex-matched volunteers, revealed that 
serum exosomes from both patients and healthy subjects exhibited the characteris-
tics similar to the exosomes from human gastric epithelial cells GES-1 cultured with 
CagA+ H. pylori in their morphology using transmission electron microscopy, size 
distribution using a Zetasizer Nano ZS instrument, and unique biomarkers (HSP70 
and CD9) using Western blotting. As expected, CagA protein was detected in the 
serum exosomes from patients with CagA+ H. pylori infection, but not from control 
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subjects using Western blotting analysis. When labeled human serum exosomes 
with PKH67 were cultured with HUVECs, a significant amount of PKH67-labeled 
exosomes was present in HUVECs using 3-D confocal microscopy after 12 hours of 
culture, confirming the entry of serum exosomes into HUVECs. Treatment with 
Figure 2. 
Exosomes from human gastric epithelial cells GES-1 cultured with CagA+ H. pylori significantly inhibited 
endothelial cell function in vitro. Western blotting analysis (A) and immunofluorescence staining (B) with 3-D 
confocal microscope demonstrated that the unique H. pylori virulence factor CagA entered into GES-1 after culture 
with CagA+ H. pylori. Exosomes isolated from the conditioned media of GES-1 cultured with CagA+ H. pylori 
displayed typical features for exosomes including characteristic biomarkers HSP70 and CD9 by western blotting 
(C), morphologies on transmission electron microscopy (D), and size using a Zetasizer Nano ZS instrument 
(E). Western blotting analysis confirmed the presence of CagA protein in the exosomes from the conditioned 
media of GES-1 cultured with CagA+ H. pylori, but not in the ones from GES-1-conditioned media without 
CagA+ H. pylori (C). PKH67-labeled GES-1-derived exosomes (green) were incubated with HUVECs (30 μg 
protein/5 × 104 cells), and a significant amount of PKH67-labeled exosomes were detected inside the HUVECs 
as visualized using a 3-D confocal microscope (F), confirming that the exosomes entered into the cells. Treatment 
of HUVECs with CagA protein-containing exosomes (50ug/ml) from GES-1-conditioned media for 24 hours 
significantly inhibited the function of HUVECs with decreased migration (G, scale bars = 200 μm), tube formation 
(H, scale bars = 200 μm), and proliferation (I, scale bars = 50 μm). NC: Normal control; CagA+ HP: CagA+ 
H. pylori; GES-1: Human gastric epithelial cells; HUVEC: Human umbilical vein endothelial cell; Exo-CM: 
Exosomes derived from conditioned medium. *p < 0.05, **p < 0.01, ***p < 0.001. Data were presented as mean ± SE, 
n = 3 independent experiments (experiment was repeated 3 times for every measurement). [adopted from (55) with 
permission].
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serum-derived CagA-containing exosomes from patients with CagA+ H. pylori 
infection significantly inhibited the function of HUVECs with decreased migra-
tion, proliferation, and tube formation. Of note, culture with serum exosomes from 
healthy control subjects also moderately and yet significantly inhibited endothelial 
function with decreased migration, tube formation, and proliferation, suggesting 
that some endogenous substances in the normal serum exosomes could also lead to 
endothelial dysfunction. However, the serum exosomes from patients with CagA+ 
H. pylori infection exhibited significantly greater inhibitory effects on endothelial 
functions than the ones from healthy subjects.
Studies were also performed to determine if blocking exosomes release with 
GW4869 in vivo could improve endothelial function in mice with CagA+ H. pylori 
infection [55]. Indeed, treatment with GW4869 significantly decreased the level of 
serum exosomes in the mice with H. pylori infection (Figure 3A), and effectively 
preserved Ach-induced endothelium-dependent relaxation of the aorta without 
change in NTG-induced endothelium-independent relaxation (Figure 3B and C). 
These findings suggest that H. pylori (especially CagA+ H. pylori) infection could 
lead to significant endothelial dysfunction in both patients and mice through 
exosomes-mediated mechanisms.
6. Effect of H. pylori infection on other cardiovascular risk factors
It is not surprising that H. pylori infection increases the risk for atherosclerosis 
and other CVDs including HTN and stroke. It has been reported that H. pylori 
infection promotes the release of IL-1, IL-6, TNF-ɑ, and other cytokines, and 
activates local and systemic inflammatory response, thus leading to endothelial 
dysfunction and atherosclerosis [81–83]. H. pylori infection could also lead to 
malabsorption of vitamin B12, which could increase serum level of homocysteine, 
and promote the development and progression of atherosclerosis [84]. In addi-
tion, H. pylori could enhance the oxidation of low-density lipoproteins (LDL) 
and increase atherosclerotic plaque formation with decreased plaque stability [85, 
86]. We also observed that the levels of LDL-cholesterol in patients with H. pylori 
infection were significantly higher than those without H. pylori infection, while the 
level of high-density lipoprotein cholesterol (HDL-C) were significantly decreased 
in the patients with H. pylori infection than those without H. pylori infection [47]. 
Patients with H. pylori seropositivity were shown to have increased brachial-ankle 
Figure 3. 
Inhibition of exosome secretion by GW4869 significantly improved endothelium -dependent vascular 
relaxation in mice with CagA+ H. pylori infection. Treatment with GW4869 significantly decreased the serum 
exosome level in the mice with CagA+ H. pylori infection (A) as reflected by the significantly decreased total 
exosome protein levels (***p < 0.001 by one-way ANOVA with Bonferroni’s test), and significantly improved 
acetylcholine (ach)-induced endothelium-dependent relaxation (B) of the aorta in the mice with CagA+ H. 
pylori infection without change in nitroglycerin (NTG)-induced endothelium-independent relaxation (C). 
*p < 0.05 (when CagA+ H. pylori + GW4869 group compared with CagA+ H. pylori + DMSO group). Ach: 
Acetylcholine; NTG: Nitroglycerin; DMSO: Dimethylsulfoxide (solubilizer of GW4869). Data shown were 
mean ± SE. n = 8 mice for control group and 10 mice for other groups. [adopted from (55) with permission].
11
Helicobacter pylori Infection and Endothelial Dysfunction
DOI: http://dx.doi.org/10.5772/intechopen.97260
pulse wave velocity (a marker of atherosclerosis), and impaired glucose metabolism 
[87]. It is believed that H. pylori could interact with gastric epithelial cells to up-
regulate the expression of adhesion molecules, and secrete cytokines, which could 
activate leukocytes, damage the vascular endothelium, aggravate local and system-
atic inflammatory responses, and thus promote the development and progression of 
atherosclerosis and related CVDs.
7. Significance and clinical implications
It is very concerning that cardiovascular mortality has been increasing since 
2010 especially for males for unknown reasons [6]. It is also reported that the 
patients with ST elevation myocardial infarction over the past 20 years are get-
ting younger [5]. The reasons for this reverse trend in cardiovascular mortality 
and mobility have yet to be defined. H. pylori infection selectively increased the 
risk for carotid atherosclerosis in young male patients (≤ 50 years), not in older 
males or female patients. A recent study [33] that analyzed a large database with 
a study population of 208,196 showed that the mortality rate was significantly 
lower in patients with early eradication of H. pylori infection. The cumulative 
CAD rate was significantly decreased in younger patients (<65 years old) with H. 
pylori eradication therapy within 1 year of infection compared to those patients 
without eradication at all. Interestingly, the treatment of H. pylori eradication 
did not have a benefit in older patients (>65 years old). These data strongly 
suggested that H. pylori infection could be a significant risk factor for endothelial 
dysfunction, atherosclerosis and CAD in young patients, and could provide 
a potential explanation for young patients who develop CAD without a clear 
etiology. It is unclear why H. pylori infection does not increase the risk for ath-
erosclerosis for patients older than 50 years. It is possible that other significant 
risk factors like DM, HTN, and hyperlipidemia play a dominant role that could 
mask the contribution of H. pylori infection to the development and progres-
sion of atherosclerosis in this age group of patients. Further studies are needed 
to investigate the mechanism(s) on the selective effect of H. pylori infection on 
atherosclerosis in young population.
There are substantial sex differences in many CVDs including (but not limited 
to) myocardial infarctions, heart failure, hypertension, and cardiac hypertrophy 
[88]. It is well known that premenopausal women are relatively protected from 
CVDs when compared to men. Typically, women are almost 10 years older than 
men when they have their first myocardial infarction [89]. It was believed that the 
decreased cardiovascular morbidity and mortality in young females was due to 
possible cardio-protective effects of estrogen [90]. However, several large clinical 
studies, including the HERS trials and the Women’s Health Initiative study [91, 92] 
showed that hormone replacement therapies (HRT) had no cardiovascular benefit 
in post-menopausal women. In contrast, there might have been an increased risk 
of CAD during the first year of HRT, and there was an increased risk of nonfatal 
ventricular arrhythmias among the women on HRT [91]. Thus, the mechanism(s) 
for decreased CVD risk in premenopausal women is still unclear. The prevalence 
of H. pylori infection was the same in males and females, and yet, H. pylori infec-
tion only increased the risk for carotid atherosclerosis in male patients≤50 years, 
not in older males or female patients. It is possible that the significant sex and age 
difference in the development of atherosclerosis associated with H. pylori infection 
may be one of the reasons for decreased risk for CAD in young females. Further 
studies are needed to confirm these findings with both patients and experimental 
animal models.
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Currently available data strongly suggest that H. pylori infection is an important 
risk factor for endothelial dysfunction and CVDs especially in young male popula-
tion. The available data also provide solid evidence to support screening young male 
population for H. pylori infection once a year and treating accordingly for early 
prevention of CVDs especially premature atherosclerosis associated with H. pylori 
infection.
8. Conclusions
H. pylori infection significantly increases the risk for CVDs including atheroscle-
rosis, HTN, CHD, cerebrovascular disease, and peripheral arterial diseases espe-
cially in younger patients (< 65 years old). H. pylori infection significantly impairs 
vascular endothelial function through multiple mechanisms including increased 
ROS production and oxidative stress, inflammation, decreased NO formation, 
modification of the expression of cytokines and miRNAs, interruption of lipid and 
glucose metabolisms, and exosomes-mediated pathways as shown in Figure 4. 
Endothelial dysfunction associated with H. pylori infection is reversible in both 
animal model and human subjects if the infection could be eliminated in a timely 
fashion (within one year of infection for human subjects and 6 months for mice). 
Accumulating data suggests that H. pylori infection is an additional risk factor for 
endothelial dysfunction and CVDs. Screening young male population for H. pylori 
infection once a year and treating accordingly could be an effective approach for 
early prevention of CVDs especially premature atherosclerosis associated with H. 
pylori infection.
Figure 4. 
Schematic illustration of the mechanism on endothelial dysfunction and atherosclerosis associated with H. 
pylori infection. It is proposed that H. pylori infection could impair endothelial function through exosome-
mediated mechanisms. CagA protein is only from CagA+ H. pylori, and could serve as an ideal tracking 
molecule for exosome trafficking in vivo. CagA+ H. pylori translocate CagA protein into gastric epithelial cells 
(GES-1). CagA-containing exosomes are released into circulation from GES-1, then enter into endothelial 
cells, leading to endothelial dysfunction. H. pylori Infection could also decrease endothelial function through 
increased production of reactive oxygen species, oxidative stress, and inflammation, decreased cellular nitric 
oxide formation, modification of the expression of cytokines and miRNAs, and interruption of lipid and 
glucose metabolisms. [adopted and modified from (47) with permission].
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